NauseaNCT04994262
The Effect on Thirst, Nausea-Vomiting and Comfort Levels of Menthol Lozenge Applied After Extubation
A study testing Menthol Lozenge in people with Nausea and Vomiting, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
Trial summary
It is reported that approximately 17.5 million people die worldwide each year due to cardiovascular diseases, including ischemic heart disease, cerebrovascular disease and rheumatic heart disease. The most preferred method in the treatment of coronary artery disease is Coronary Artery Bypass Graft (CABG) surgery. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- What is being tested?
- Menthol Lozenge
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 118 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 May 2020to 1 May 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- between the ages of 18-65
- Undergoing elective coronary artery bypass graft surgery
- Extubated within the first 8 hours in the intensive care unit after CABG surgery
- Class ASA I, II and III
- Mallampati classification I and II
- Have no swallowing difficulties and Mann swallowing assessment score ≥95
- Glasgow Coma Scale with 15 points
- Patients who agree to participate in the study will be included.
Who cannot join
- Body Mass Index of 40
- Have a history of allergies
- Having severe nausea and vomiting at the time of application Illiterate
- Having communication problems
- Patients with psychiatric problems and using drugs will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect on Thirst, Nausea-Vomiting, Hemodynamic Parameters, and Comfort Levels of Menthol Lozenge Applied After Extubation to Patients to Undergoing Cardiovascular Surgery
It is reported that approximately 17.5 million people die worldwide each year due to cardiovascular diseases, including ischemic heart disease, cerebrovascular disease and rheumatic heart disease. The most preferred method in the treatment of coronary artery disease is Coronary Artery Bypass Graft (CABG) surgery. This procedure routinely requires general anesthesia and endotracheal intubation. Patients due to these practices often experience nausea-vomiting and thirst after extubation. It is stated that menthol application, which is a low cost, easy to apply and safe method, can be effective in the management of these complications. As a result of the literature review, there is no study evaluating the effectiveness of the menthol lozenge in quenching thirst after extubation and in the management of nausea and vomiting. In this study, it is aimed to develop methods that accelerate the postoperative recovery by proving the effect of oral menthol lozenge intake after extubation on thirst, nausea-vomiting, physiological parameters and comfort level in patients undergoing CABG surgery. The universe of this randomized controlled study was planned by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create patients who underwent CABG surgery. His sample, on the same dates, was Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create a total of 118 patients hospitalized in the Cardiovascular Surgery (Postoperative) Intensive Care Unit and undergoing CABG surgery that meet the inclusion criteria. Participants will be divided into two equal groups as intervention (n = 59) and control (n = 59) groups. Patient Information Form, Intraoperative Patient Evaluation Form, Visual Analogue Scale (VAS) for evaluation of thirst and nausea-vomiting, Physiological Parameter Control Form, Analgesic-Antiemetic Use Control Form, General Comfort Scale Short Form will be used for data collection. The intervention group will be given a lozenge containing menthol orally at the 30th, 60th and 90th minutes after extubation. Thirst, nausea-vomiting, physiological parameters, analgesic and antiemetic consumption and comfort levels of all patients will be evaluated. The data obtained from the study will be analyzed with appropriate statistical methods using the SPSS for Windows 22.0 program (Statistical Package for the Social Sciences).
Read the detailed description
The aim of this study is to determine the effect of oral menthol lozenge administered after extubation on thirst, nausea-vomiting, physiological parameters and comfort level, as well as analgesic and antiemetic consumption in patients who underwent cardiovascular surgery. With this research, it is aimed to increase patient comfort by providing evidence of the effect of low-cost oral menthol lozenge intake on the feeling of thirst, nausea-vomiting, analgesic and antiemetic integration after extubation on physiological parameters.
Practices aimed at eliminating many problems such as thirst, sore throat, nausea and vomiting experienced in the early postoperative period positively affect the physical, psychospirical, environmental, sociocultural comfort of the patient and strengthen their health-oriented behaviors. It has been reported that there is a relationship between health-enhancing behaviors and providing comfort. It is observed that patients who undergo surgical procedures experience many problems in the postoperative period, their comfort level decreases and they are widely affected, from prolonged hospital stay to mortality. There are many studies in the literature aimed at accelerating the recovery in the perioperative process and increasing patient satisfaction.
Complications such as thirst and nausea and vomiting, which are seen in the postoperative period and can be quite disturbing by patients, can be overlooked in clinical observations. It is planned to prove the effectiveness of the use of low-cost and easy-to-apply menthol lozenge in the management of these complications. In the light of the literature review, menthol was found to be effective in gastrointestinal system disorders, pain management, and dehydration. The use of oral menthol containing lozenge in quenching thirst after extubation, in the management of postoperative nausea and vomiting, and in improving patient comfort, as well as analgesic-antiemetic consumption and evaluation of physiological parameters are the original value of this study.
The universe of the research was carried out by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create patients who underwent CABG surgery. His sample, on the same dates, was Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create a total of 118 patients hospitalized in the Cardiovascular Surgery (Postoperative) Intensive Care Unit and undergoing CABG surgery that meet the inclusion criteria.
Sampling calculation was done with G Power 3.1.9.7 package program. Based on the VAS score averages in the study conducted by Aydın (2016), the sample that will represent the population was calculated as 0.05 significance level, the power of the study 80% and the effect size 0.46 (medium level) at the 95% confidence interval. As a result of the statistical analysis, it was calculated that the study should be carried out with a minimum of 118 patients, 59 in the experimental group and 59 in the control group.
t tests - Means: Difference between two independent means (two groups) Analysis: A priori: Compute required sample size Input: Tail(s) = One Effect size d = 0.4617784 α err prob = 0.05 Power (1-β err prob) = 0.80 Allocation ratio N2/N1 = 1 Output: Noncentrality parameter δ = 2.5080987 Critical t = 1.6580957 Df = 116 Sample size group 1 = 59 Sample size group 2 = 59 Total sample size = 118 Actual power = 0.8019408 Randomization Method: After obtaining the permission of the ethics committee, patients who meet the inclusion criteria in the study and who have received written informed consent to participate in the study will be divided into two groups in equal numbers with the computer-based randomization method.
- Being tested
- Menthol Lozenge
- Keywords
- Nausea, Vomiting, Menthol, Thirst, CABG
- Medical subject headings
- Nausea, Vomiting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Menthol LozengeOther
In the study, "Oka Menthol", a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.
Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Patients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time.
Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes.
Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded.
Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form. Receives: Other: Menthol Lozenge |
| Control Group | No intervention | Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time. Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly. Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analog Scale (VAS) for Evaluating Thirst Level
The VAS is 10 cm long and graded on a horizontal line.
Thirst Score Comment:
0-3 points Mild Thirst 4-6 points Moderate Thirst 7-10 points Severe Thirst
Measured: Change from baseline (30 minutes) thirst level at 120 minutes after extubation.
Visual Analogue Scale (VAS) for Evaluation of Nausea and Vomiting
It is used to convert numerically non-measurable values into a numerical state. Interpretation of nausea severity score averages
Nausea Severity Interpretation:
0-1 No nausea 2-4 Mild nausea 5-7 Moderate nausea 8-10 Severe nausea
Measured: Change from baseline (30 minutes) nausea and vomiting at 120 minutes after extubation.
General Comfort Scale Short Form (GAS-SF)
The sc items), relaxation (9 items), and overcoming problems (10 items). In the evaluation of the scale consisting of positive and negative items, negative items are summarized with reverse coding. The lowest possible value of 1 indicates low comfort, and the highest value of 6 indicates high comfort.ale includes the sub-dimensions of relaxation, relaxation (9
Measured: This test will be applied on the second day after the surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2021
- Study start1 May 2020
- Primary completion1 May 2021
- Study completion1 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NauseaStudies of the same condition, open and under way.
- More trials run by Saglik Bilimleri UniversitesiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 118 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saglik Bilimleri Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elif Gezginci, Saglik Bilimleri Universitesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04994262
- Sponsor's protocol ID
- 21-14
- Status last verified
- Aug 2021
- First submitted
- 5 May 2021
- Last updated
- 6 Aug 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect on Thirst, Nausea-Vomiting, Hemodynamic Parameters, and Comfort Levels of Menthol Lozenge Applied After Extubation to Patients to Undergoing Cardiovascular Surgery
- ClinicalTrials.gov ID
- NCT04994262
- Acronym / sponsor ID
- 21-14
- Keywords
- Nausea, Vomiting, Menthol, Thirst, CABG
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 118 participants (actual)
- Lead sponsor
- Saglik Bilimleri UniversitesiUniversity, hospital or other
- Study start
- 1 May 2020 (actual)
- Primary completion
- 1 May 2021 (actual)
- Study completion
- 1 May 2021 (actual)
- First posted
- 6 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is reported that approximately 17.5 million people die worldwide each year due to cardiovascular diseases, including ischemic heart disease, cerebrovascular disease and rheumatic heart disease. The most preferred method in the treatment of coronary artery disease is Coronary Artery Bypass Graft (CABG) surgery. This procedure routinely requires general anesthesia and endotracheal intubation. Patients due to these practices often experience nausea-vomiting and thirst after extubation. It is stated that menthol application, which is a low cost, easy to apply and safe method, can be effective in the management of these complications. As a result of the literature review, there is no study evaluating the effectiveness of the menthol lozenge in quenching thirst after extubation and in the management of nausea and vomiting. In this study, it is aimed to develop methods that accelerate the postoperative recovery by proving the effect of oral menthol lozenge intake after extubation on thirst, nausea-vomiting, physiological parameters and comfort level in patients undergoing CABG surgery. The universe of this randomized controlled study was planned by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create patients who underwent CABG surgery. His sample, on the same dates, was Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create a total of 118 patients hospitalized in the Cardiovascular Surgery (Postoperative) Intensive Care Unit and undergoing CABG surgery that meet the inclusion criteria. Participants will be divided into two equal groups as intervention (n = 59) and control (n = 59) groups. Patient Information Form, Intraoperative Patient Evaluation Form, Visual Analogue Scale (VAS) for evaluation of thirst and nausea-vomiting, Physiological Parameter Control Form, Analgesic-Antiemetic Use Control Form, General Comfort Scale Short Form will be used for data collection. The intervention group will be given a lozenge containing menthol orally at the 30th, 60th and 90th minutes after extubation. Thirst, nausea-vomiting, physiological parameters, analgesic and antiemetic consumption and comfort levels of all patients will be evaluated. The data obtained from the study will be analyzed with appropriate statistical methods using the SPSS for Windows 22.0 program (Statistical Package for the Social Sciences).
Detailed description
The aim of this study is to determine the effect of oral menthol lozenge administered after extubation on thirst, nausea-vomiting, physiological parameters and comfort level, as well as analgesic and antiemetic consumption in patients who underwent cardiovascular surgery. With this research, it is aimed to increase patient comfort by providing evidence of the effect of low-cost oral menthol lozenge intake on the feeling of thirst, nausea-vomiting, analgesic and antiemetic integration after extubation on physiological parameters.
Practices aimed at eliminating many problems such as thirst, sore throat, nausea and vomiting experienced in the early postoperative period positively affect the physical, psychospirical, environmental, sociocultural comfort of the patient and strengthen their health-oriented behaviors. It has been reported that there is a relationship between health-enhancing behaviors and providing comfort. It is observed that patients who undergo surgical procedures experience many problems in the postoperative period, their comfort level decreases and they are widely affected, from prolonged hospital stay to mortality. There are many studies in the literature aimed at accelerating the recovery in the perioperative process and increasing patient satisfaction.
Complications such as thirst and nausea and vomiting, which are seen in the postoperative period and can be quite disturbing by patients, can be overlooked in clinical observations. It is planned to prove the effectiveness of the use of low-cost and easy-to-apply menthol lozenge in the management of these complications. In the light of the literature review, menthol was found to be effective in gastrointestinal system disorders, pain management, and dehydration. The use of oral menthol containing lozenge in quenching thirst after extubation, in the management of postoperative nausea and vomiting, and in improving patient comfort, as well as analgesic-antiemetic consumption and evaluation of physiological parameters are the original value of this study.
The universe of the research was carried out by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create patients who underwent CABG surgery. His sample, on the same dates, was Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital will create a total of 118 patients hospitalized in the Cardiovascular Surgery (Postoperative) Intensive Care Unit and undergoing CABG surgery that meet the inclusion criteria.
Sampling calculation was done with G Power 3.1.9.7 package program. Based on the VAS score averages in the study conducted by Aydın (2016), the sample that will represent the population was calculated as 0.05 significance level, the power of the study 80% and the effect size 0.46 (medium level) at the 95% confidence interval. As a result of the statistical analysis, it was calculated that the study should be carried out with a minimum of 118 patients, 59 in the experimental group and 59 in the control group.
t tests - Means: Difference between two independent means (two groups) Analysis: A priori: Compute required sample size Input: Tail(s) = One Effect size d = 0.4617784 α err prob = 0.05 Power (1-β err prob) = 0.80 Allocation ratio N2/N1 = 1 Output: Noncentrality parameter δ = 2.5080987 Critical t = 1.6580957 Df = 116 Sample size group 1 = 59 Sample size group 2 = 59 Total sample size = 118 Actual power = 0.8019408 Randomization Method: After obtaining the permission of the ethics committee, patients who meet the inclusion criteria in the study and who have received written informed consent to participate in the study will be divided into two groups in equal numbers with the computer-based randomization method.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Other: Menthol LozengePatients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time. Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes. Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded. Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form. |
| Control Group | No intervention | –Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time. Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly. Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- between the ages of 18-65
- Undergoing elective coronary artery bypass graft surgery
- Extubated within the first 8 hours in the intensive care unit after CABG surgery
- Class ASA I, II and III
- Mallampati classification I and II
Key exclusion criteria (5 listed)
- Body Mass Index of 40
- Have a history of allergies
- Having severe nausea and vomiting at the time of application Illiterate
- Having communication problems
- Patients with psychiatric problems and using drugs will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Menthol LozengeIn the study, "Oka Menthol", a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose. Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant. | Other | Intervention Group |
Primary outcome
Visual Analog Scale (VAS) for Evaluating Thirst Level
Time frame: Change from baseline (30 minutes) thirst level at 120 minutes after extubation.
The VAS is 10 cm long and graded on a horizontal line. Thirst Score Comment: 0-3 points Mild Thirst 4-6 points Moderate Thirst 7-10 points Severe Thirst
Visual Analogue Scale (VAS) for Evaluation of Nausea and Vomiting
Time frame: Change from baseline (30 minutes) nausea and vomiting at 120 minutes after extubation.
It is used to convert numerically non-measurable values into a numerical state. Interpretation of nausea severity score averages Nausea Severity Interpretation: 0-1 No nausea 2-4 Mild nausea 5-7 Moderate nausea 8-10 Severe nausea
General Comfort Scale Short Form (GAS-SF)
Time frame: This test will be applied on the second day after the surgery.
The sc items), relaxation (9 items), and overcoming problems (10 items). In the evaluation of the scale consisting of positive and negative items, negative items are summarized with reverse coding. The lowest possible value of 1 indicates low comfort, and the highest value of 6 indicates high comfort.ale includes the sub-dimensions of relaxation, relaxation (9
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2021.
- Individual participant dataSharing planned: No
Related trials for Nausea
Not yet recruitingPhase 2
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Breast Cancer
RecruitingPhase 4
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Nausea With Vomiting Chemotherapy-Induced
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Not yet recruitingObservational study
Preoperative Gastric Volume and PONV in Pediatric Appendectomy Cases
Postoperative Nausea and Vomiting
RecruitingPhase 2
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Nausea, Vomiting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Menthol Lozenge in people with Nausea and Vomiting, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analog Scale (VAS) for Evaluating Thirst Level (time frame: Change from baseline (30 minutes) thirst level at 120 minutes after extubation.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2021.